Compare ACV & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACV | RCEL |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 272.3M | 114.3M |
| IPO Year | N/A | N/A |
| Metric | ACV | RCEL |
|---|---|---|
| Price | $25.95 | $3.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $11.75 |
| AVG Volume (30 Days) | 38.8K | ★ 201.4K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 9.20% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $72,401,000.00 |
| Revenue This Year | N/A | $13.12 |
| Revenue Next Year | N/A | $27.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 20.59 |
| 52 Week Low | $16.82 | $3.33 |
| 52 Week High | $23.74 | $14.16 |
| Indicator | ACV | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 53.11 | 37.63 |
| Support Level | $26.05 | $3.33 |
| Resistance Level | $26.76 | $3.58 |
| Average True Range (ATR) | 0.45 | 0.18 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 53.47 | 22.31 |
Virtus AllianzGI Diversified Income & Convertible Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation while seeking to provide downside protection against capital loss. It invests in a diversified portfolio of convertible securities, income-producing equity securities, and income-producing debt and other instruments of varying maturities, of which a majority of the managed assets are invested in convertibles.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.